NuPathe Stock Price, News & Analysis (NASDAQ:PATH)

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About NuPathe (NASDAQ:PATH)

NuPathe, Inc. develops therapeutics for diseases of the central nervous system including neurological and psychiatric disorders. The Companys products are NP201 for the continuous symptomatic treatment of Parkinson's disease and NP202 for the long-term treatment of schizophrenia and bipolar disorder. The Company completed a pivotal Phase III clinical trial for Zelrix, an active, single-use transdermal sumatriptan patch for the treatment of acute migraine.

Receive PATH News and Ratings via Email

Sign-up to receive the latest news and ratings for PATH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:PATH
CUSIPN/A
Phone+1-610-2320800

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A

NuPathe (NASDAQ:PATH) Frequently Asked Questions

What is NuPathe's stock symbol?

NuPathe trades on the NASDAQ under the ticker symbol "PATH."

Who are some of NuPathe's key competitors?

How do I buy NuPathe stock?

Shares of NuPathe can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact NuPathe?

NuPathe's mailing address is 7 Great Valley Pkwy Ste 300, MALVERN, PA 19355-1425, United States. The healthcare company can be reached via phone at +1-610-2320800.


MarketBeat Community Rating for NuPathe (PATH)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  31 (Vote Outperform)
Underperform Votes:  38 (Vote Underperform)
Total Votes:  69
MarketBeat's community ratings are surveys of what our community members think about NuPathe and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

NuPathe (NASDAQ:PATH) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AHoldHold
Consensus Rating Score: N/AN/A2.002.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/A$5.00$5.00
Price Target Upside: N/AN/A17.65% upside17.65% upside

NuPathe (NASDAQ:PATH) Consensus Price Target History

Price Target History for NuPathe (NASDAQ:PATH)

NuPathe (NASDAQ:PATH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/28/2016WedbushDowngradeOutperform -> Neutral$8.00 -> $5.00N/AView Rating Details
(Data available from 12/16/2015 forward)

Earnings

NuPathe (NASDAQ:PATH) Earnings History and Estimates Chart

Earnings by Quarter for NuPathe (NASDAQ:PATH)

NuPathe (NASDAQ PATH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2013Q3($0.20)($0.25)ViewListenView Earnings Details
8/8/2013Q2 2013($0.20)($0.16)ViewN/AView Earnings Details
5/14/2013Q1 2013($0.17)($0.68)ViewN/AView Earnings Details
3/26/2013Q4 2012($0.33)($1.16)ViewN/AView Earnings Details
11/12/2012Q312($0.38)($0.42)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

NuPathe (NASDAQ:PATH) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for NuPathe (NASDAQ:PATH)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for NuPathe (NASDAQ PATH)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

NuPathe (NASDAQ PATH) News Headlines

Source:

SEC Filings

NuPathe (NASDAQ:PATH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

NuPathe (NASDAQ:PATH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

NuPathe (NASDAQ PATH) Stock Chart for Saturday, December, 16, 2017

Loading chart…

This page was last updated on 12/16/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.